To include your compound in the COVID-19 Resource Center, submit it here.

Cstone gets Chinese rights to Blueprint clinical pipeline

Blueprint Medicines Corp. (NASDAQ:BPMC) granted CStone Pharmaceuticals Co. Ltd. (Suzhou, China) exclusive rights to all three of Blueprint's clinical candidates in a deal potentially worth more than $386 million.

CStone gained exclusive rights to develop and commercialize avapritinib, BLU-667 and BLU-554 in mainland China, including

Read the full 442 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers